查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1689621

肝纤维化及NASH/MASH药物市场:2025-2035年

Liver Fibrosis & NASH/MASH Drugs Market Report 2025-2035
出版日期: | 出版商: Visiongain | 英文 245 Pages | 商品交期: 最快1-2个工作天内

价格

预计 2025 年全球肝纤维化和 NASH/MASH 药物市场规模将达到 183 亿美元，预测期内复合年增长率为 10.0%。

NASH/MASH 药物核准面临的监管课题与市场障碍：

NASH/MASH 是日益严重的公共卫生危机，病情会发展为肝纤维化和肝硬化。 MASH 主要与第 2 型糖尿病和心血管疾病有关。在临床试验中，NASH 药物将透过测量与肝臟相关结果相关的综合终点来证明其减缓疾病进展或预防其发作的能力。

但由于目前NASH尚无有效治疗方法，美国FDA有另一条核准途径。此途径依赖透过肝臟切片检查对疾病进展进行组织病理学评估作为替代终点和临床试验期间的良好临床结果。因此，美国 FDA 核准的药物必须符合其主要终点，即证明纤维化 a*1 期有所改善且 MASH 没有恶化，或 MASH 有所消退且纤维化没有恶化。

然而，欧洲药品管理局（EMA）的监管要求与美国 FDA 不同。 EMA 要求满足两个主要终点，即 NASH 完全消退以及纤维化改善。全球范围内临床试验要求缺乏统一性，这对製药公司构成了重大课题。

本报告提供全球肝纤维化及NASH/MASH药物的市场调查，提供全市场概要，影响市场成长因素及市场机会分析，市场规模的转变·预测，各种区分·地区/各主要国家的详细分析，竞争情形，主要企业简介等资讯。

目录

第1章 报告概要

第2章 摘要整理

第3章 市场概要

  • 主要调查结果
  • 市场动态
  • 影响分析
    • 市场推动要素
    • 阻碍市场要素
    • 市场机会
  • 法律规章上架构
  • 波特的五力分析
  • PEST分析

第4章 肝纤维化用药物市场分析:各疾病类型

  • 主要调查结果
  • 市场魅力指数
  • 市场规模的转变·预测
  • 抗病毒药物
  • 酒精性肝疾病 (ALD)
  • 自体免疫性肝疾病
  • 抗氧化剂
  • 药物性肝损伤 (DILI)
    • 市场规模的转变·预测:各地区
    • 市场占有率:各地区

第5章 NASH/MASH药市场分析

  • 主要调查结果
  • 肝纤维化/NASH//MASH药物的规模:市规模预测
  • 维他命E和PIOGLITAZONE
  • Rezdiffra
  • Semaglutide (Ozempic)
  • Tirzepatide
  • Pemvidutide
  • Lanifibranor
  • Belapectin
  • Efruxifermin
  • Pegozafermin
  • Denifanstat
  • 联合治疗

第6章 NASH/MASH医药品市场上管线医药品的分析

  • 主要调查结果
  • 到2024年为止的各种临床试验阶段有的NASH/MASH开发平台(管线)的数
  • 阶段III临床试验:NASH/MASH市场
  • 阶段II临床试验:NASH/MASH市场
  • 开发平台(管线)联合治疗:NASH/MASH市场
  • 开发平台(管线)联合治疗:肝硬化伴随的NASH/MASH市场
  • 新加入厂商者/新技术临床试验:NASH/MASH市场
  • 临床试验:药物的再利用肝纤维化市场

第7章 NASH//MASH药物市场分析:各主要国家

  • 主要调查结果
  • NASH/MASH市场:线维化的各阶段 (%)
  • NASH/MASH地区分析:市场占有率 (%)
    • 按市场规模:各地区
  • 美国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 德国
  • 日本
  • 中国

第8章 肝纤维化治疗药市场分析:各终端用户

  • 主要调查结果
  • 市场魅力指数
  • 市场规模的转变·预测
  • 医院药局
  • 专门药局
  • 其他的药局
    • 市场规模的转变·预测:各地区
    • 市场占有率:各地区

第9章 肝及NASH//MASH药物市场分析

  • 主要调查结果
  • 市场规模的转变·预测

第10章 北美的肝纤维化市场分析

第11章 欧洲的肝纤维化及NASH/MASH药物市场分析

第12章 亚太地区的肝纤维化及NASH/MASH药物市场分析

第13章 南美的肝纤维化及NASH/MASH药物市场分析

第14章 中东·非洲的肝纤维化及NASH/MASH药物市场分析

第15章 企业简介

  • 竞争情形
  • Madrigal Pharmaceuticals
  • Novo Nordisk.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Inventiva Pharma
  • Galectin Therapeutics
  • Galmed Pharmaceutical
  • Akero Therapeutics
  • AstraZeneca plc
  • .Altimmune
  • Boehringer Ingelheim

第16章 总论·建议

  • Visiongain的总论
  • 参与企业的建议
Product Code: PHA1366

The global Liver Fibrosis & NASH/MASH Drugs Market Report 2025-2035 market is estimated at US$18.3 billion in 2025 and is projected to grow at a CAGR of 10.0% during the forecast period 2025-2035.

The Liver Fibrosis & NASH/MASH Drugs Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Regulatory Challenges and Market Barriers in NASH/MASH Drug Approval

NASH/MASH is an escalating public health crisis, with the disease progressively leading to liver fibrosis and cirrhosis. MASH is primarily associated with type 2 diabetes and cardiovascular diseases. During clinical trials, NASH drugs must demonstrate their ability to delay disease progression and prevent its onset by measuring composite endpoints related to liver-associated outcomes.

However, due to the absence of effective treatments currently available for NASH, the U.S. FDA has provided an alternative approval pathway. This pathway relies on histopathological assessment of disease progression through liver biopsies as surrogate endpoints, along with positive clinical outcomes during trials. Consequently, the U.S. FDA approves drugs that meet the primary endpoints by either demonstrating an improvement of ,a*1 stage in fibrosis with no worsening of MASH or achieving MASH resolution without worsening fibrosis.

In contrast, the European Medicines Agency (EMA) has different regulatory requirements compared to the U.S. FDA. The EMA mandates that both primary endpoints be met, requiring complete resolution of NASH along with improvement in fibrosis. The lack of uniformity in clinical trial requirements at a global level poses a significant challenge for pharmaceutical companies.

Beyond meeting these endpoints, the effects of new therapies must also be evaluated for their impact on type 2 diabetes and cardiovascular risks. For complete regulatory approval, clinical outcomes should include mortality rates, cirrhosis progression reports, and other liver-related events. This necessitates long-term patient monitoring and follow-up during clinical trials, with the added risk of product failure in confirmatory trials. Additionally, patients receiving a placebo may be required to wait despite the drug being commercially available.

Thus, the lack of regulatory uniformity and the complexity of NASH as a disease hinder the timely commercialization of these drugs.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the Liver Fibrosis & NASH/MASH Drugs market evolving?
  • What is driving and restraining the Liver Fibrosis & NASH/MASH Drugs market?
  • How will each Liver Fibrosis & NASH/MASH Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
  • How will the market shares for each Liver Fibrosis & NASH/MASH Drugs submarket develop from 2025 to 2035?
  • What will be the main driver for the overall market from 2025 to 2035?
  • Will leading Liver Fibrosis & NASH/MASH Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Liver Fibrosis & NASH/MASH Drugs projects for these leading companies?
  • How will the industry evolve during the period between 2025 and 2035? What are the implications of
  • Liver Fibrosis & NASH/MASH Drugs projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Liver Fibrosis & NASH/MASH Drugs market?
  • Where is the Liver Fibrosis & NASH/MASH Drugs market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Liver Fibrosis & NASH/MASH Drugs market today, and over the next 10 years:

  • Our 245-page report provides 112 tables, 138 charts exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2035 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

  • Liver Fibrosis Disease Drug Type
  • Antiviral
  • Alcoholic Liver Disease
  • Antioxidants
  • Immunosuppressants
  • Drug Induced Liver Injury
  • NASH/MASH Market by Drugs by Type
  • Vitamin E & Pioglitazone
  • Rezdiffra
  • Semaglutide
  • Tirzepatide
  • Pemvidutide
  • Lanifibranor
  • Belapectin
  • Efruxifermin
  • Pegozafermin
  • Denifanstat
  • Combination Therapies
  • NASH/MASH Drugs by Clinical Pipeline
  • Phase III
  • Phase II
  • New Entrants
  • Combination Therapies
  • Repurposing Drugs
  • Liver Fibrosis Drugs Market by End Users
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles for some of the leading companies in the Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035, with a focus on this segment of these companies' operations.

  • Leading companies and the potential for market growth
  • List of Companies Profiled in the Report
  • Madrigal Pharmaceuticals
  • Novo Nordisk
  • Eli Lilly
  • Gilead Sciences Inc.
  • Galectin Therapeutics
  • Galmed Pharmaceuticals
  • Akero Therapeutics
  • AstraZeneca plc
  • Altimmune
  • Boehringer Ingelheim

Overall world revenue for Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035 in terms of value the market will surpass US$18.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035 report help you?
  • In summary, our 240+ page report provides you with the following knowledge:
  • Revenue forecasts to 2035 for Liver Fibrosis & NASH/MASH Drugs Market 2025 to 2035, with forecasts for Type and Indication, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2035 for five regional and 20 key national markets - See forecasts for the Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, South Korea and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 11 of the major companies involved in the Liver Fibrosis & NASH/MASH Drugs Market, 2025 to 2035.
  • Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Liver Fibrosis / NASH / MASH Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Rise in Prevalence of Liver Diseases
      • 3.3.1.2 Rise in diabetes and obesity pandemic consequently leading to rise in MASH
      • 3.3.1.3 Early diagnosis via adoption of Non-invasive diagnostics tests
      • 3.3.1.4 Growing adoption of Artificial Intelligence for Liver Disease Diagnosis
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Cost of Diagnosis & Drugs Limits the Growth of the Market
      • 3.3.2.2 Delayed Diagnosis of MASH & Fibrosis
      • 3.3.2.3 Regulatory Hurdles
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Diagnostic & Biopharma Partnerships
      • 3.3.3.2 Nano-Particle Based Drug Delivery
  • 3.4 Regulatory Framework
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Liver Fibrosis Drugs Market Analysis, by Disease Type

  • 4.1 Key Findings
  • 4.2 Product Type Segment: Market Attractiveness Index
  • 4.3 Liver Fibrosis / NASH / MASH drugs market Size Estimation and Forecast by Drug Type
  • 4.4 Antivirals
    • 4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.4.2 Market Share by Region, 2025 & 2035 (%)
  • 4.5 Alcoholic Liver Disease (ALD)
    • 4.5.1 Market Size by Region, 2025-2035 (US$ Million)
    • 4.5.2 Market Share by Region, 2025 & 2035 (%)
  • 4.6 Autoimmune Liver Disease
    • 4.6.1 Market Size by Region, 2025-2035 (US$ Million)
    • 4.6.2 Market Share by Region, 2025 & 2035 (%)
  • 4.7 Anti-Oxidant Modulators
    • 4.7.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.7.2 Market Share by Region, 2025 & 2035 (%)
  • 4.8 Drug Induced Liver Injury (DILI)
    • 4.8.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.8.2 Market Share by Region, 2025 & 2035 (%)

5 NASH / MASH Drugs Market Analysis

  • 5.1 Key Findings
  • 5.2 Liver Fibrosis / NASH / MASH Drugs Market Size Estimation and Forecast by Drugs
  • 5.3 Vitamin E & Pioglitazone
  • 5.4 Rezdiffra
  • 5.5 Semaglutide (Ozempic)
  • 5.6 Tirzepatide
  • 5.7 Pemvidutide
  • 5.8 Lanifibranor
  • 5.9 Belapectin
  • 5.10 Efruxifermin
  • 5.11 Pegozafermin
  • 5.12 Denifanstat
  • 5.13 Combination Therapies

6 NASH / MASH Drugs Market Analysis by Pipeline Drugs

  • 6.1 Key Findings
  • 6.2 Number of NASH/MASH Pipeline in Various Clinical Trial Stage,2024
  • 6.3 Phase III Clinical Trials : NASH/MASH Market
  • 6.4 Phase II Clinical Trials : NASH/MASH Market
  • 6.5 Pipeline Combination Therapies: NASH/MASH Market
  • 6.6 Pipeline Combination Therapies: NASH/MASH Market with Cirrhosis
  • 6.7 New Entrants / New Technology Clinical Trials : NASH/MASH Market
  • 6.8 Clinical Trials : Repurposing Drugs Liver Fibrosis Market

7 NASH / MASH Drugs Market Analysis by Major Countries

  • 7.1 Key Findings
  • 7.2 NASH/MASH Market : By Stage of Fibrosis (%)
  • 7.3 NASH/MASH Geographic Analysis : By Market Share (%)
    • 7.3.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 7.4 U.S.
  • 7.5 UK
  • 7.6 France
  • 7.7 Italy
  • 7.8 Spain
  • 7.9 Germany
  • 7.10 Japan
  • 7.11 China

8 Liver Fibrosis Drugs Market Analysis by End-users

  • 8.1 Key Findings
  • 8.2 End-users Segment: Market Attractiveness Index
  • 8.3 Liver Fibrosis drugs market Size Estimation and Forecast by End-users
  • 8.4 Hospital Pharmacies
    • 8.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 8.4.2 Market Share by Region, 2025 & 2035 (%)
  • 8.5 Speciality Pharmacies
    • 8.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 8.5.2 Market Share by Region, 2025 & 2035 (%)
  • 8.6 Other Pharmacies
    • 8.6.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 8.6.2 Market Share by Region, 2025 & 2035 (%)

9 Liver Fibrosis / NASH / MASH Drugs Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Liver Fibrosis Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Liver fibrosis Drugs market Attractiveness Index
  • 10.3 North America Liver Fibrosis Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 North America Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
  • 10.5 North America Liver Fibrosis Drugs Market Size Estimation and Forecast by Indications
  • 10.6 North America Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
  • 10.7 U.S. Liver Fibrosis Drugs Market Analysis
  • 10.8 Canada Liver Fibrosis Drugs market Analysis

11 Europe Liver Fibrosis / NASH / MASH Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Liver Fibrosis Drugs Market Attractiveness Index
  • 11.3 Europe Liver Fibrosis Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 11.4 Europe Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
  • 11.5 Europe Liver Fibrosis drugs market Size Estimation and Forecast by Indications
  • 11.6 Europe Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
  • 11.7 Germany Liver fibrosis Drugs market Analysis
  • 11.8 France Liver fibrosis Drugs market Analysis
  • 11.9 UK Liver fibrosis Drugs market Analysis
  • 11.10 Italy Liver fibrosis Drugs market Analysis
  • 11.11 Spain Liver fibrosis Drugs market Analysis
  • 11.12 Russia Liver Fibrosis Drugs Market Analysis
  • 11.13 Rest of Europe Liver Fibrosis Drugs Market Analysis

12 Asia Pacific Liver Fibrosis Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Liver Fibrosis drugs market Attractiveness Index
  • 12.3 Asia Pacific Liver Fibrosis Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 12.4 Asia Pacific Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
  • 12.5 Asia-Pacific Liver Fibrosis drugs market Size Estimation and Forecast by Indications
  • 12.6 Asia-Pacific Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
  • 12.7 Japan Liver fibrosis Drugs market Analysis
  • 12.8 China Liver fibrosis Drugs market Analysis
  • 12.9 India Liver fibrosis Drugs market Analysis
  • 12.10 Australia Liver Fibrosis Drugs Market Analysis
  • 12.11 South Korea Liver Fibrosis Drugs Market Analysis
  • 12.12 Rest of Asia-Pacific Liver fibrosis Drugs market Analysis

13 Latin America Liver Fibrosis Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Liver Fibrosis Drugs Market Attractiveness Index
  • 13.3 Latin America Liver Fibrosis Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 13.4 Latin America Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
  • 13.5 Latin America Liver Fibrosis drugs market Size Estimation and Forecast by Indications
  • 13.6 Latin America Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
  • 13.7 Brazil Liver Fibrosis Drugs Market Analysis
  • 13.8 Mexico Liver fibrosis Drugs market Analysis
  • 13.9 Rest of Latin America Fibrosis Drugs market Analysis

14 MEA Liver fibrosis Drugs Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Liver Fibrosis Drugs Market Attractiveness Index
  • 14.3 MEA Liver Fibrosis Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 14.4 MEA Liver Fibrosis Drugs Market Size Estimation and Forecast by Country
  • 14.5 MEA Liver Fibrosis Drugs market Size Estimation and Forecast by Indications
  • 14.6 MEA Liver Fibrosis Drugs Market Size Estimation and Forecast by End-users
  • 14.7 GCC Liver Fibrosis drugs market Analysis
  • 14.8 South Africa Liver Fibrosis Drugs Market Analysis
  • 14.9 Rest of MEA Fibrosis Drugs Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2024
  • 15.2 Madrigal Pharmaceuticals
    • 15.2.1 Company Snapshot
    • 15.2.2 Company Overview
    • 15.2.3 Product Benchmarking
    • 15.2.4 SWOT Analysis
    • 15.2.5 Strategic Outlook
  • 15.3 Novo Nordisk.
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2019-2023
      • 15.3.3.2 Regional Market Share, 2023 (%)
    • 15.3.4 Product Benchmarking
    • 15.3.5 SWOT Analysis
    • 15.3.6 Pipeline Analysis
    • 15.3.7 Strategic Outlook
  • 15.4 Eli Lilly and Company
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2019-2023
      • 15.4.3.2 R&D, 2019-2023
      • 15.4.3.3 Regional Market Share, 2023 (%)
    • 15.4.4 Pipeline Analysis
    • 15.4.5 Strategic Outlook
    • 15.4.6 SWOT Analysis
  • 15.5 Gilead Sciences, Inc.
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2018-2023
      • 15.5.3.2 R&D, 2018-2023
      • 15.5.3.3 Regional Market Shares, 2023
      • 15.5.3.4 Business Segment Market Shares, 2023
    • 15.5.4 Product Benchmarking
    • 15.5.5 Strategic Outlook
  • 15.6 Inventiva Pharma
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2018-2023
    • 15.6.4 Product Benchmarking
  • 15.7 Galectin Therapeutics
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
    • 15.7.4 Product Benchmarking
    • 15.7.5 Pipeline Analysis
    • 15.7.6 Strategic Outlook
  • 15.8 Galmed Pharmaceutical
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
    • 15.8.4 Product Benchmarking
    • 15.8.5 Pipeline Analysis
    • 15.8.6 Strategic Outlook
  • 15.9 Akero Therapeutics
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
    • 15.9.4 Product Benchmarking
    • 15.9.5 Pipeline Analysis
    • 15.9.6 Strategic Outlook
  • 15.10 AstraZeneca plc
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2017-2023
      • 15.10.3.2 R&D, 2017-2023
      • 15.10.3.3 Regional Market Shares, 2023
      • 15.10.3.4 Business Segment Market Shares, 2023
    • 15.10.4 Pipeline Analysis
  • 15.11 .Altimmune
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Pipeline Analysis
    • 15.11.4 Strategic Outlook
  • 15.12 Boehringer Ingelheim
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
      • 15.12.2.1 Net Revenue, 2019-2023
      • 15.12.2.2 R&D, 2019-2023
      • 15.12.2.3 Regional Market Shares, 2023
      • 15.12.2.4 Business Segment Market Shares, 2023
    • 15.12.3 Pipeline Analysis
    • 15.12.4 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players

List of Tables

  • Table 1 Liver fibrosis Drugs market Snapshot, 2025 & 2035 (US$ Billion, CAGR %)
  • Table 2 NASH/MASH Market Snapshot, 2025 & 2035 (US$ Billion, CAGR %)
  • Table 3 Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 4 Commercially Available Hepatitis B Drugs
  • Table 5 Commercially Available Hepatitis C Drugs
  • Table 6 Emerging Drugs for Hepatitis C Infection
  • Table 7 Pipeline Drugs for Hepatitis B
  • Table 8 Antiviral Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 9 Alcohol Liver Disease Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 10 Immunosuppressants (Autoimmune Liver Disease) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 11 Anti-Oxidant Inflammatory Modulator Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 12 DILI Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 13 NASH / MASH Market Forecast by Drugs, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 14 Vitamin E & Pioglitazone Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 15 Rezdiffra Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 16 Semaglutide (Ozempic) Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 17 Tirzepatide Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 18 Pemvidutide Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 19 Lanifibranor Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 20 Belapectin Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 21 Efruxifermin Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 22 Pegozafermin Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 23 Denifanstat Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 24 Combination Therapies & Other Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 25 Pipeline Phase III : Clinical Trial Drugs for MASH
  • Table 26 Pipeline Phase II : Clinical Trial Drugs for MASH
  • Table 27 Pipeline Combination Therapies : Clinical Trial Drugs for MASH
  • Table 28 Pipeline Combination Therapies : Clinical Trial Drugs for MASH with Cirrhosis
  • Table 29 New Entrants : Clinical Trial Drugs for MASH
  • Table 30 Clinical Trials : Repurposing Drugs: Liver Fibrosis
  • Table 31 Global NASH/MASH Market Forecast by Major Countries, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 32 U.S. NASH/MASH Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 33 UK NASH/MASH Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 34 France NASH/MASH Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 35 Italy NASH/MASH Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 36 Spain NASH/MASH Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 37 German NASH/MASH Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 38 Japan NASH/MASH Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 39 China NASH/MASH Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 40 Liver Fibrosis Drugs Market Forecast by End-users, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 41 Hospital Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 42 Specialty Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 43 Other Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 44 Liver Fibrosis Drugs Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 45 North America Liver Fibrosis Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 46 North America Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 47 North America Liver Fibrosis Drugs Market Forecast by End-users, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 48 U.S. Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 49 Canada Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 50 Europe Liver Fibrosis Drugs Market Forecast by Country, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 51 Europe Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 52 European Liver Fibrosis Drugs Market Forecast by End User, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 53 Germany Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 54 France Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 55 UK Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 56 Italy Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 57 Spain Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 58 Russia Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 59 Rest of Europe Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 60 Asia-Pacific Liver Fibrosis Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 61 Asia-Pacific Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 62 Asia Liver Fibrosis Drugs Market Forecast by Distribution, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 63 Japan Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 64 China Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 65 India Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 66 Australia Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 67 South Korea Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 68 Rest of Asia Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 69 Latin America Liver Fibrosis Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 70 Latin America Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 71 Latin America Liver Fibrosis Drugs Market Forecast by Distribution, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 72 Brazil Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 73 Mexico Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 74 Rest of Latin America Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 75 MEA Liver Fibrosis Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 76 MEA Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 77 MEA Liver Fibrosis Drugs Market Forecast by End-users, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 78 GCC Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 79 South Africa Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 80 Rest MEA Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 81 Madrigal Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Madrigal Pharmaceutical Company Limited: Strategic Outlook
  • Table 83 Novo Nordisk.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84 Novo Nordisk.: Product Benchmarking
  • Table 85 Novo Nordisk : Clinical Pipeline NASH/MASH
  • Table 86 Novo Nordisk : Strategic Outlook
  • Table 87 Eli Lilly: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Eli Lilly : Clinical Pipeline NASH/MASH
  • Table 89 Eli Lilly & Company: Strategic Outlook
  • Table 90 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Gilead : Clinical Pipeline NASH/MASH
  • Table 92 Gilead Sciences, Inc.: Product Benchmarking
  • Table 93 Gilead Sciences, Inc.: Strategic Outlook
  • Table 94 Inventiva Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Inventiva: Clinical Pipeline NASH/MASH
  • Table 96 Inventiva Pharma.: Strategic Outlook
  • Table 97 Galectin Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 Galectin Therapeutics: Clinical Pipeline NASH/MASH
  • Table 99 Galectin Therapeutics: Strategic Outlook
  • Table 100 Galmed Pharmaceutical.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 Galmed Pharmaceuticals : Clinical Pipeline NASH/MASH
  • Table 102 Galmed Pharmaceutical Strategic Outlook
  • Table 103 Akero Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 Akero Pharmaceuticals : Clinical Pipeline NASH/MASH
  • Table 105 Akero Therapeutics: Strategic Outlook
  • Table 106 AstraZeneca plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 AstraZeneca plc: Clinical Pipeline NASH/MASH
  • Table 108 Altimmune: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 Altimmune : Clinical Pipeline NASH/MASH
  • Table 110 Boehringer Ingelheim.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Boehringer Ingelheim : Clinical Pipeline NASH/MASH
  • Table 112 Boehringer Ingelheim : Strategic Outlook

List of Figures

  • Figure 1 Liver Fibrosis & NASH/MASH Drugs Market Segmentation
  • Figure 2 Liver Fibrosis Drugs Market by Product Type: Market Attractiveness Index
  • Figure 3 Liver Fibrosis Drugs market by End-users: Market Attractiveness Index
  • Figure 4 Liver fibrosis Drugs market Attractiveness Index by Region
  • Figure 5 Liver Fibrosis / NASH / MASH Drugs Market: Market Dynamics
  • Figure 6 Liver Fibrosis / NASH / MASH Drugs Market: Impact Analysis
  • Figure 7 Liver Fibrosis/ NASH Market: Porter's Five Forces Analysis
  • Figure 8 Liver Fibrosis / NASH / MASH Drugs Market: PEST Analysis
  • Figure 9 Liver Fibrosis Drugs Market by Product Type: Market Attractiveness Index
  • Figure 10 Liver Fibrosis / NASH / MASH Drugs Market Forecast by Drug Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 11 Liver Fibrosis / NASH / MASH Drugs Market Share Forecast by Product Type, 2024, 2029, 2034 (%)
  • Figure 12 Antiviral Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 13 Antiviral Segment Market Forecast by Region, 2025 & 2035 (%)
  • Figure 14 Alcohol Liver Disease Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Figure 15 Alcohol Liver Disease Market Forecast by Region, 2025 & 2035 (%)
  • Figure 16 Immunosuppressants (Autoimmune Liver Disease) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Figure 17 Immunosuppressants (Autoimmune Liver Disease) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%), 2025 & 2035 (%)
  • Figure 18 Anti-Oxidant Inflammatory Modulator Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 19 Anti-Oxidant Inflammatory Modulator Segment Market Forecast by Region, 2025 & 2035 (%)
  • Figure 20 Drug Induced Liver Injury Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 21 Drug Induced Liver Injury (DILI) Segment Market Forecast by Region, 2025 & 2035 (%)
  • Figure 22 NASH / MASH Drugs market Forecast by Drug Type, 2025-2035 (US$ Billion)
  • Figure 23 Vitamin E & Pioglitazone Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 24 Rezdiffra Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 25 Semaglutide Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 26 Tirzepatide Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 27 Pemvidutide Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 28 Lanifibranor Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 29 Belapectin Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 30 Efruxifermin Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 31 Pegozafermin Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 32 Denifanstat Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 33 Combination Therapies & Others Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 34 NASH / MASH Pipeline in Clinical Trial Stage I to III (2024)
  • Figure 35 Liver Fibrosis / NASH / MASH Drugs Market Share Forecast by Stages of Fibrosis 2025, 2030, 2035 (%)
  • Figure 36 NASH/ MASH (Geographical Analysis, 2024, By Market Share (%)
  • Figure 37 U.S. NASH / MASH drugs market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 38 UK NASH / MASH drugs market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 39 France NASH / MASH drugs market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 40 Italy NASH / MASH drugs market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 41 Spain NASH / MASH drugs market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 42 German NASH / MASH drugs market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 43 Japan NASH / MASH drugs market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 44 China NASH / MASH drugs market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 45 Liver Fibrosis Drugs Market by End-users: Market Attractiveness Index
  • Figure 46 Liver Fibrosis Drugs Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 47 Liver fibrosis Drugs market Share Forecast by End-users, 2024, 2029, 2034 (%)
  • Figure 48 Hospital Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 49 Hospital Pharmacies Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 50 Specialty Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 51 Specialty Pharmacies Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 52 Other Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 53 Other Pharmacies Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 54 Liver Fibrosis Drugs Market Forecast by Region 2025, 2030, 2035 (Revenue, CAGR%)
  • Figure 55 Liver Fibrosis Market Share Forecast by Region 2025, 2030, 2035 (%)
  • Figure 56 Liver Fibrosis Drugs Market by Region, 2025-2035 (US$ Billion)
  • Figure 57 North America Liver Fibrosis Drugs Market Attractiveness Index
  • Figure 58 North America Liver Fibrosis Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 59 North America Liver Fibrosis / NASH / MASH Drugs Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
  • Figure 60 North America Liver Fibrosis Drugs Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 61 North America Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 62 North America Liver Fibrosis Drugs Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 63 North America Liver Fibrosis Drugs market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 64 North America Liver Fibrosis / NASH / MASH Drugs Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 65 U.S. Liver Fibrosis Drugs market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 66 Canada Liver Fibrosis drugs market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 67 Europe Liver fibrosis Drugs Market Attractiveness Index
  • Figure 68 Europe Liver Fibrosis Drugs market by Country, 2025, 2030 & 2035 (US$ Billion)
  • Figure 69 Europe Liver Fibrosis Drugs market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 70 Europe Liver Fibrosis Drugs market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 71 Europe Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 72 Europe Liver Fibrosis Drugs Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 73 Europe Liver Fibrosis Drugs market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 74 Europe Liver Fibrosis Drugs Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 75 Germany Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 76 France Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 77 UK Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 78 Italy Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 79 Spain Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 80 Russia Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 81 Rest of Europe Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 82 Asia Pacific Liver Fibrosis Drugs Market Attractiveness Index
  • Figure 83 Asia Pacific Liver Fibrosis Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 84 Asia Pacific Liver Fibrosis Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 85 Asia Pacific Liver Fibrosis Drugs Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 86 Asia-Pacific Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 87 Asia-Pacific Liver Fibrosis Drugs Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 88 Asia-Pacific Liver Fibrosis Drugs market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 89 Asia-Pacific Liver Fibrosis Drugs Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 90 Japan Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 91 China Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 92 India Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 93 Australia Liver Fibrosis Drugs market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 94 South Korea Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 95 Rest of Asia-Pacific Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 96 Latin America Liver Fibrosis Drugs Market Attractiveness Index
  • Figure 97 Latin America Liver Fibrosis Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 98 Latin America Liver Fibrosis Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 99 Latin America Liver Fibrosis Drugs Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 100 Latin America Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 101 Latin America Liver Fibrosis Drugs Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 102 Latin America Liver Fibrosis Drugs market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 103 Latin America Liver Fibrosis Drugs Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 104 Brazil Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 105 Mexico Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 106 Rest of Latin America Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 107 MEA Liver Fibrosis Drugs Market Attractiveness Index
  • Figure 108 MEA Liver Fibrosis Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 109 MEA Liver Fibrosis Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 110 MEA Liver Fibrosis Drugs Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 111 MEA Liver Fibrosis Drugs Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 112 MEA Liver Fibrosis Drugs Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 113 MEA Liver Fibrosis Drugs market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 114 MEA Liver Fibrosis Drugs Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 115 GCC Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 116 South Africa Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 117 Rest of MEA Liver Fibrosis Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 118 Liver Fibrosis Drugs market: Company Share/Ranking, 2024
  • Figure 119 NASH Drugs market: Company Share/Ranking, 2024
  • Figure 120 Madrigal Pharmaceuticals : SWOT Analysis
  • Figure 121 Novo Nordisk: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 122 Novo Nordisk Regional Market Share, 2023 (%)
  • Figure 123 Novo Nordisk, Inc.: SWOT Analysis
  • Figure 124 Eli Lilly & Company: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 125 Eli Lilly & Company R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 126 Eli Lilly Regional Market Share, 2023 (%)
  • Figure 127 Eli Lilly & Company: SWOT Analysis
  • Figure 128 Gilead Sciences, Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 129 Gilead Sciences, Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 130 Gilead Sciences, Inc.: Regional Market Shares (%), 2023
  • Figure 131 Gilead Sciences, Inc.: Business Segment Market Shares (%), 2023
  • Figure 132 AstraZeneca plc: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 133 AstraZeneca plc: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 134 AstraZeneca plc: Regional Market Shares, 2023
  • Figure 136 Boehringer Ingelheim: Net Revenue, 2019-2023 (US$ Million, AGR%)
  • Figure 137 Boehringer Ingelheim: R&D, 2019-2023 (US$ Million, AGR%)
  • Figure 138 Boehringer Ingelheim: Regional Market Shares, 2023